We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study
Read MoreHide Full Article
Editas Medicine, Inc. (EDIT - Free Report) announced that it has dosed the first pediatric patient in the phase I/II BRILLIANCE study evaluating its lead candidate, EDIT-101, for the treatment of blindness due to Leber congenital amaurosis 10 (LCA10).
The BRILLIANCE study is evaluating the safety of EDIT-101 for the treatment of LCA10 — a rare genetic illness that causes blindness. Currently, there is no therapy approved for treating LCA10.
The company plans to complete dosing in the pediatric mid-dose cohort of the BRILLIANCE study in the first half of 2022. Dosing in the pediatric high-dose cohort is expected to begin later this year.
Shares of Editas were down 4.3% on Monday following the announcement of the news. The stock has plunged 33.9% so far this year compared with the industry’s decline of 12.1%.
Image Source: Zacks Investment Research
Last June, Editas started enrollment in the first of two planned pediatric cohorts in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating LCA10.
In September 2021, Editas announced initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of blindness due to LCA10. Early observations from subjects treated in the mid-dose cohort of the study demonstrated clinical evidence of gene editing led by visual improvements.
An update from the BRILLIANCE study is expected in the second half of 2022.
This apart, Editas is evaluating the safety and efficacy of another pipeline candidate, EDIT-301, for treating sickle cell disease.
In December 2021, the FDA cleared the investigational new drug application for EDIT-301 to treat transfusion-dependent beta thalassemia (“TDT”). The company plans to begin a phase I/II study to evaluate the safety, tolerability and preliminary efficacy of EDIT-301 for treating TDT patients. Dosing in the study is expected to begin later in 2022.
Editas has no approved product in its portfolio at the moment. Therefore, pipeline development remains in key focus for the company.
The Zacks Consensus Estimate for Galera Therapeutics’ loss per share has narrowed 30.6% for 2022 over the past 60 days.
Earnings of GRTX surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.
Applied Therapeutics’ loss per share estimates have narrowed 11.9% for 2022 over the past 60 days.
Earnings of Applied Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 over the past 60 days. The VYGR stock has skyrocketed 203.7% year to date.
Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study
Editas Medicine, Inc. (EDIT - Free Report) announced that it has dosed the first pediatric patient in the phase I/II BRILLIANCE study evaluating its lead candidate, EDIT-101, for the treatment of blindness due to Leber congenital amaurosis 10 (LCA10).
The BRILLIANCE study is evaluating the safety of EDIT-101 for the treatment of LCA10 — a rare genetic illness that causes blindness. Currently, there is no therapy approved for treating LCA10.
The company plans to complete dosing in the pediatric mid-dose cohort of the BRILLIANCE study in the first half of 2022. Dosing in the pediatric high-dose cohort is expected to begin later this year.
Shares of Editas were down 4.3% on Monday following the announcement of the news. The stock has plunged 33.9% so far this year compared with the industry’s decline of 12.1%.
Image Source: Zacks Investment Research
Last June, Editas started enrollment in the first of two planned pediatric cohorts in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating LCA10.
In September 2021, Editas announced initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of blindness due to LCA10. Early observations from subjects treated in the mid-dose cohort of the study demonstrated clinical evidence of gene editing led by visual improvements.
An update from the BRILLIANCE study is expected in the second half of 2022.
This apart, Editas is evaluating the safety and efficacy of another pipeline candidate, EDIT-301, for treating sickle cell disease.
In December 2021, the FDA cleared the investigational new drug application for EDIT-301 to treat transfusion-dependent beta thalassemia (“TDT”). The company plans to begin a phase I/II study to evaluate the safety, tolerability and preliminary efficacy of EDIT-301 for treating TDT patients. Dosing in the study is expected to begin later in 2022.
Editas has no approved product in its portfolio at the moment. Therefore, pipeline development remains in key focus for the company.
Zacks Rank & Stocks to Consider
Editas currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Galera Therapeutics, Inc. (GRTX - Free Report) , Applied Therapeutics, Inc. (APLT - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Galera Therapeutics’ loss per share has narrowed 30.6% for 2022 over the past 60 days.
Earnings of GRTX surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.
Applied Therapeutics’ loss per share estimates have narrowed 11.9% for 2022 over the past 60 days.
Earnings of Applied Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 over the past 60 days. The VYGR stock has skyrocketed 203.7% year to date.
Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.